Enhertu has a black box warning for interstitial lung disease and See CPT/HCPCS Code section below. Policy/ Coverage: Effective Aug
This Clinical Policy Bulletin addresses fam-trastuzumab deruxtecan-nxki (Enhertu) for commercial medical plans. CPT Codes / HCPCS Codes / ICD-10 Codes. HCPCS
J3247: Permanent J-code for the IV formulation of COSENTYX Effective J, for all sites of care. If COSENTYX is administered on or after J, the permanent J-code replaces the miscellaneous J-code J3590.
This document addresses the use of Enhertu (fam-trastuzumab deruxtecan-nxki). Coding Reviewed -Added HCPCS codes J9358 (Effective 7/1
Enhertu) for those with HER2-positive metastatic breast cancer with J. Piccart, MD, PhD. Efficacy outcomes including overall
by SA Hurvitz 2024 Cited by 351Baselga, J ∙ Cortés, J ∙ Kim, SB ∙ et al. Pertuzumab plus 15. Daiichi Sankyo. Enhertu (fam-trastuzumab deruxtecan-nxki) for
ATC code. L01XC41. Mechanism of action. Enhertu, trastuzumab deruxtecan, is a HER2-targeted antibody-drug conjugate (ADC). The antibody is a
Reference article title: ENHERTU. Package insert. Daiichi Sankyo, Inc; 2024. Reference article URL: www.ENHERTUPI.com. Vial size. NDC. J-code. One 100 mg single
Results showed a confirmed ORR of 76.0% with Enhertu and 84.0% with Enhertu in combination with pertuzumab. The 12-month PFS rate was 80.8% with Enhertu monotherapy and 89.4% with Enhertu and pertuzumab.
R.